Last updated 2026-06-18
- Went public
- Acquired Colospan, Jun 2026
- Public offering
Total raised
$150.3M
Last: Public Offering Jul 2023
Stage
Public
Founded
2000
Headcount
10
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
Galmed Pharmaceuticals is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. The company is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.
Q&A
- What is Galmed Pharmaceuticals' primary focus?
- Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases.
- What is Galmed Pharmaceuticals' lead drug candidate?
- Galmed Pharmaceuticals' lead compound is Aramchol, a drug candidate for the treatment of NASH and fibrosis, currently in a Phase 3 registrational study.
- When did Galmed Pharmaceuticals go public?
- Galmed Pharmaceuticals went public on NASDAQ in March 2014.
- What was Galmed Pharmaceuticals' most recent public offering?
- In July 2023, Galmed Pharmaceuticals announced the pricing of a $7 million public offering.
- What is Galmed Pharmaceuticals' collaboration with the Hebrew University?
- Galmed Pharmaceuticals is collaborating with the Hebrew University on the development of Amilo-5MER, a 5 amino acid synthetic peptide, and recently initiated a first-in-human study for it.
- Has Galmed Pharmaceuticals been granted any recent patents?
- Yes, in February 2023, Galmed Pharmaceuticals announced the issuance of a new composition of matter patent for Aramchol meglumine salt.
- What is the employee count for Galmed Pharmaceuticals?
- Galmed Pharmaceuticals has 1-10 employees.
- Who is the current President & CEO of Galmed Pharmaceuticals?
- Allen Baharaff is the President & CEO of Galmed Pharmaceuticals.
Team · 6
Senior CMC Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
metabolic-diseasedrug-discoverypharmaceuticalsmicrobiomebiopharmaceuticaloral-drugscrohn-s-diseasediabetespharma-companiesinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Founded | 2000-1 |
|---|---|
| Employees (exact) | 10 |
| Market cap | $4.1M |
| Status reason | Public on NASDAQ on Mar, 2014 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Colospan | 2026-06 |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Jul 2023 | ||||
| Feb 2021 | ||||
| Jun 2018 | ||||
| Jan 2018 | ||||
| Mar 2014 |